Clinical Trial Update: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial results compare lazertinib with subcutaneous amivantamab to intravenous amivantamab in patients with EGFR-mutated advanced or metastatic non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Lazertinib (lazertinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-02